대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	NEPHROPROTECTIVE TREATMENT WITH DAPAGLIFLOZIN IN PATIENTS WITH DIABETIC KIDNEY DISEASE
저자	Olimkhon Sharapov
출판정보	2025; 2025(1):
키워드	ALBUMINURIA, DIABETIC KIDNEY DISEASE, SGLT2 INHIBITORS, DAPAGLIFLOZIN, NEPHROPROTECTION
초록	Albuminuria in patients with diabetes presents a higher risk for adverse renal and cardiovascular (CV) outcomes. Sodium glucose co-transporter 2 (SGLT2) inhibitors demonstrate improved albuminuria and reduces the risk of end-stage renal disease in patients with chronic kidney disease. The study aim was the impact of the SGLT2 inhibitor dapagliflozin on urine albumin-to-creatinine ratio (UACR) and GFR decline. In the single center trial, total 132 participants with CKD and type 2 diabetes (T2D) were randomly assigned to dapagliflozin (n = 78) 10 mg once daily or placebo (n = 54). Kidney inclusion criteria were eGFR 30--60ml/min/1.73 m2 and any UACR. The primary end point was a composite of sustained decline in eGFR >50%, end-stage renal disease, or kidney or cardiovascular death. Percentage treatment difference was estimated by geometric mean ratio for the overall cohort and by eGFR and UACR subgroups. Progression/regression of UACR were assessed. Hazard ratios, 95% confidence intervals (CI), and p-values were estimated by Cox proportional hazards model. Median baseline eGFR was 42.3ml/min/1.73 m2, with 5% at <30ml/min/1.73 m2. At baseline, median UACR was 103 mg/g, and 1/4 of patients had normoalbuminuric, 2/4 had micro, and 1/4 had macroalbuminuria. Median follow up was 18 months. The UACR difference for dapagliflozin vs placebo was -25.1% (95% CI -27.5, -23.2; p< 0.001). Reductions were similar across eGFRs. In UACR 30-299mg/g and >300mg/g, reductions were significant in dapagliflozin (p< 0.001). Progression risk was lower and regression risk higher in dapagliflozin vs placebo (p<0.001). Dapagliflozin significantly slowed long-term eGFR decline in patients with CKD with T2D compared with placebo, and significantly reduced UACR and had favorable effects on UACR progression and regression.
원문(PDF)	PDF 원문보기

목록

위로가기